RCUS vs XNCR
RCUS: A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in late-stage trials. XNCR: Xencor is a clinical-stage biopharmaceutical company leveraging its proprietary XmAb antibody engineering platform to develop innovative multi-specific therapeutics for cancer and autoimmune diseases.
Side-by-side fundamentals
| Metric | RCUS | XNCR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $29.97 | $19.51 | |
| Market cap as of 2026-07-23 | $3.7B | $1.4B | |
| Net margin as of 2026-07-23 | -156.4% | -177.1% | RCUS higher |
| Operating margin as of 2026-07-23 | -168.6% | -222.4% | RCUS higher |
| ROE as of 2026-07-23 | -69.0% | -28.8% | XNCR higher |
| ROA as of 2026-07-23 | -35.3% | -20.5% | XNCR higher |
| Debt / equity as of 2026-07-23 | 0.19 | 0.21 | RCUS lower |
| Revenue growth (YoY) as of 2026-07-23 | -15.1% | -25.4% | RCUS higher |
| Revenue CAGR (3y) SEC XBRL | -4.6% | -8.6% | RCUS higher |
| Beta as of 2026-07-23 | 0.81 | 0.84 | |
| 1-year return as of 2026-07-22 close | +218.4% | +112.1% | RCUS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.